E
Emilio Martín Mola
Researcher at Hospital Universitario La Paz
Publications - 36
Citations - 2849
Emilio Martín Mola is an academic researcher from Hospital Universitario La Paz. The author has contributed to research in topics: Rheumatoid arthritis & Evidence-based medicine. The author has an hindex of 14, co-authored 36 publications receiving 2741 citations.
Papers
More filters
Journal ArticleDOI
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report
Juan J. Gomez-Reino,Loreto Carmona,Vicente Rodríguez Valverde,Emilio Martín Mola,Maria Dolores Montero +4 more
TL;DR: Therapy with infliximab is associated with an increased risk of active TB, and proper measures are needed to prevent and manage this adverse event.
Journal ArticleDOI
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Loreto Carmona,Juan J. Gomez-Reino,Vicente Rodriguez-Valverde,Dolores Montero,Eliseo Pascual‐Gomez,Emilio Martín Mola,Luis Carreño,M.E. Figueroa +7 more
TL;DR: Strategies to treat latent TB infection that are tailored to the at-risk population can effectively and safely lessen the likelihood of active TB in patients treated with TNF antagonists.
Journal ArticleDOI
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
Cécile Gaujoux-Viala,Cécile Gaujoux-Viala,Josef S. Smolen,Robert Landewe,Maxime Dougados,Tore K Kvien,Emilio Martín Mola,Marieke Scholte-Voshaar,Piet L. C. M. van Riel,Laure Gossec +9 more
TL;DR: A comparison with other synthetic DMARDs was in favour of MTX, though at the tested doses MTX and leflunomide were equally effective, and MTX was well-tolerated and effective in reducing signs and symptoms, disability and structural damage.
Journal ArticleDOI
A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects
Víctor M. Martínez-Taboada,Vicente Rodriguez-Valverde,Luis Carreño,Javier López-Longo,M Figueroa,J. Belzunegui,Emilio Martín Mola,Gema Bonilla +7 more
TL;DR: Etanercept therapy was well tolerated in this aged population of patients with giant cell arteritis and the therapeutic role of etanercept in patients with GCA should be evaluated in studies with a larger number of patients.
Journal ArticleDOI
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
Maxime Dougados,Karsten Kissel,Philip G. Conaghan,Emilio Martín Mola,Georg Schett,Roberto Gerli,Michael Sejer Hansen,Howard Amital,Ricardo Machado Xavier,Orrin Troum,Corrado Bernasconi,Twj Huizinga +11 more
TL;DR: Despite a trend favouring the add-on strategy, these data suggest that both tocilizumab add- on and switch strategies led to meaningful clinical and radiographic responses.